Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer

Overview

Gastric cancer is one of the most common malignant tumors in China, and the incidence and mortality rate are second in malignant tumors. The treatment of gastric cancer need integrated multidisciplinary treatment, and surgery is the only possible curative method for gastric cancer at present. Previous studies have reported that neoadjuvant chemoradiotherapy can downstage primary tumor to increase radical resection rate in order to improve the long-term prognosis of advanced gastric cancer. However, there is no study on the application of hypo-radiotherapy to neoadjuvant radiotherapy in gastric cancer. The aim of this study was to observe the maximum tolerated dose (MTD) and dose limited toxicity (DLT) of hypo-fractionated radiotherapy for locally advanced gastric cancer.

Full Title of Study: “Phase I Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2016

Detailed Description

After enrolled in this study, the patient was first treated with radiotherapy, concurrent with oral S-1 80mg/m2/day, on radiotherapy days. 3 weeks after the end of radiotherapy, patients treated with neoadjuvant chemotherapy with oxaliplatin and S-1. Oxaliplatin is given on dose of 130mg/m2 iv on day 1; S-1 on 40-60mg po BID on day 1-14, oral. Imaging evaluation was performed 3 weeks after neoadjuvant treatment. The radical operation and surgical procedure were determined on MDT discussion. Non-operable patients continue with 3 cycles of chemotherapy, and the chemotherapy regimen can be changed. A 3 cycle of SOX adjuvant chemotherapy was performed after surgery.

Interventions

  • Radiation: Hypo-fractionated radiotherapy
    • Hypo-fractionated radiotherapy with fraction >2Gy .
  • Drug: S1
    • S-1 80mg/m2/day, orally intake on radiotherapy days.

Arms, Groups and Cohorts

  • Experimental: Hypo-fractionated radiotherapy
    • Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer

Clinical Trial Outcome Measures

Primary Measures

  • Maximum tolerated dose AND Dose limited toxicity
    • Time Frame: From date of enrollment until one month after chemo-radiotherapy
    • To assess maximum tolerated dose and dose limited toxicity of hypo-fractionated neoadjuvant radiotherapy

Secondary Measures

  • Response rate
    • Time Frame: From date of enrollment until surgery, assessed up to 2 months
    • To evaluate the pathological response rate of gastric cancer after hypo-fractionated neoadjuvant radiotherapy
  • 2-year disease-free survival
    • Time Frame: From date of enrollment until the date of first documented progression or date of relapse, whichever came first, assessed up to 24 months
    • To evaluate the 2-year disease-free survival of gastric cancer after hypo-fractionated neoadjuvant radiotherapy

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical stage T3-4N+M0 – Gastric cancer or Siewert II/III esophagogastric junction carcinoma; – Pathologically confirmed adenocarcinoma; – 18-75 years old, male or female; – Karnofsky score >= 70; – White blood cell count >= 4 x 109 / L; platelet count >= 100 x109/L; serum creatinine =< 1 x upper limit of normal, total bilirubin =< 1 x upper limit of normal, alanine aminotransferase and aspartate aminotransferase =< 2.5 x upper limit of normal, alkaline phosphatase =< 5 x upper limit of normal. Exclusion Criteria:

  • Any chemotherapy or radiotherapy history before enrollment – Siewert I EGJ cancer

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chinese Academy of Medical Sciences
  • Provider of Information About this Clinical Study
    • Principal Investigator: LI Ning, Principal Investigator – Chinese Academy of Medical Sciences
  • Overall Contact(s)
    • Jing Jin, MD, 8610-87787658, jinjing1025@csco.org.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.